Palisade Bio's PALI-2108 Shows Early Promise in Fibrostenotic Crohn’s Disease
Event summary
- Palisade Bio reported positive topline data from a Phase 1b study of PALI-2108 in fibrostenotic Crohn’s disease, showing a 47.5% reduction in SES-CD score and 40% of patients achieving endoscopic response and remission.
- The study demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment.
- Pharmacokinetic and pharmacodynamic data support once-daily oral dosing with IC90 coverage in ileal tissue and plasma.
- The company plans to advance PALI-2108 into a Phase 2 trial in moderate to severe Crohn’s disease, including evaluation of anti-fibrotic effects earlier in the disease course.
The big picture
Palisade Bio’s positive Phase 1b data for PALI-2108 highlight the potential to address both inflammatory and fibrotic components of Crohn’s disease, a significant unmet medical need. The company’s targeted PDE4 inhibitor prodrug approach aims to improve upon existing therapies by offering once-daily oral dosing and localized drug activation. If confirmed in larger studies, this strategy could position Palisade Bio as a key player in the inflammatory and fibrotic disease space, with implications for both Crohn’s disease and ulcerative colitis.
What we're watching
- Clinical Validation
- Whether the early endoscopic improvements observed with PALI-2108 can be replicated and sustained in larger Phase 2 studies.
- Regulatory Pathway
- The pace at which Palisade Bio can secure regulatory clarity for broader luminal Crohn’s disease, potentially doubling the addressable patient population.
- Competitive Positioning
- How PALI-2108’s dual anti-inflammatory and anti-fibrotic mechanism differentiates it from existing therapies targeting only inflammation.
Related topics